After reading the information all night, Fan Lunding pretended to be very confident and came to Huarui Laboratory.

He is a professional medicinal chemist and biologist, but the more he is, the more he is aware of the challenges he may face, just like all medicinal chemists and biologists face when they first come into contact with a new project, Van Lunding knew that he would face a vast sea of ​​biological literature and related basic principles.

When researchers at any company are preparing to make a certain drug, the first thing they need to do is to consult a huge amount of literature.

If you are in Zerica, researchers usually use three rooms to fill up the data, read it all and make notes.

If you are going to ask the company to spend millions of dollars to start a project and expect to spend hundreds of millions of dollars, you'd better be prepared for it.

Although he was relaxed when talking to Arnold, Van Lunding still stayed up late and did not dare to see Yang Rui after he was serious about it.

"Mr. Yang Rui." Fan Lunding came to Huarui Laboratory and greeted the Chinese researchers very politely.

Fan Lunding has read all Yang Rui's articles, and Fan Lunding has also studied the design of coenzyme Q10 made by Yang Rui.

Although he was unwilling to admit it, Fan Lunding originally devoted himself to the industry because of his slightly inferior research talent. Not to mention Yang Rui, who is at the top level in the academic world, even a big shot at ordinary levels, Fan Lunding has to pay attention to his wording.

He didn't want to be caught by Yang Rui in the wrong place, so he was ridiculed.

Unfamiliarity with deferrosterone is a key flaw that Van Lunding considers. Therefore, after saying hello, Van Lunding quickly said: "I heard that you are not clear about the process of new drug development. I have participated in an immature project before, and I hope it can help."

"Of course you can help, come in quickly. We just need you." Yang Rui greeted him enthusiastically. What he needs most now is the guide. Even if he is a blind man, as long as he can knock out the right path with a crutch, Yang Rui is very happy.

Fan Lunding asked with some guilt and some satisfaction: "What have you done?"

"We are still synthesizing more active substances. I think it's better to have a few more reserves." Yang Rui had no need to hide it.

Van Lunding slowly entered the state and said, "This is right. The more active substances, the greater the chance of finally getting the finished product."

Ordinary small companies usually prepare two or three active substances. Their goal is not to make new drugs, but to sell them to large companies after animal experiments or clinical phase one.

Large pharmaceutical companies prepare more active substances, often more than twenty types. Companies like Pfizer often prepare more than 50 active substances. The final result, such as Pfizer and others, often pass the FDA review together with the main compound, thus turning one drug into two drugs.

This is a winner-takes-all industry. Most small companies cannot last for 36 months, and large pharmaceutical companies are not always able to get what they want. Super pharmaceutical companies like Pfizer face high costs. The average cost per new drug they develop is US$700 million, far exceeding the industry average standard of US$200 million.

Compared to generic drugs that often cost only a few million yuan, the depth of the bottomless pit of the original drug cannot be measured.

Fan Lunding decided to persuade Yang Rui to do more active substances first, then open more animal experiments, and then have one more clinical trial. If the results are not achieved at this point, ordinary pharmaceutical companies will be considered to be finished.

The chance of not getting a grade is very high.

"The project team I used to work mainly developed antibiotics, but unfortunately it failed. If I still retained the experience, I should give a relatively abundant estimate of possible problems in the experiment." Fan Lunding did not continue to talk about the ferrotonide, but only talked about his own experience to avoid showing his fear.

Yang Rui agreed: "There is probably very useful. What step did you have done?"

The same problem as Arnold, Van Lunding said: "The second phase of clinical trial was not successful."

“It’s a pity.”

"It is related to our initial plan. You know, antibiotics are actually a relatively easy-to-develop drug. Because the effectiveness of the drug can be tested in vitro, no one expected that the second phase of the clinical trial would fail." Fan Lunding said and introduced some situations within the project team.

Yang Rui, Wei Zhenxue and others nodded while listening. This is indeed a rare experience.

After a while, Wei Zhenxue asked even more strangely: "You just said that the effectiveness of antibiotics does not require human testing, and you can learn in the laboratory that before you do animal experiments, you should know whether it is effective or not. Why will the second phase fail?"

"We did not predict that it is a temperature-sensitive compound. Once a patient has a high fever, its effectiveness will greatly decrease." Van Lunding shrugged, with a little embarrassed face.

Wei Zhenxue smiled without hesitation.

This is indeed a very stupid way to fail.

Huang Mao said comfortingly: "There is no way to be lucky."

Van Lunding's embarrassment flashed and then said: "There are too many problems encountered in clinical trials. Although I really want to admit that it is a factor of luck, compared with the successful project team, I think it is because we have insufficient preparations in the early stage."

"Oh, where are you referring to?"

"First of all, there is no preparation of reserve compounds." Van Lunding said that compounds with the same target but different structures, such as deferroamine and deferrorosterone, are in this relationship. This hierarchy is even more powerful than a variety of active substances.

Yang Rui shook his head: "We can't afford it."

Of course, Van Lunding knew that they could not afford it, and that those who could afford it were not small companies anymore.

Fan Lunding nodded: "Our project team also wanted to save this money to increase the success rate of a compound. I have to say that we were very optimistic about that compound back then. No one thought that, and we would eventually encounter temperature-sensitive situations."

"Didn't you do the experiment in advance?" Huang Mao asked.

"The performance of in vitro experiments is not obvious, and the environment inside the human body has obviously increased its sensitivity."

"This is an unexpected thing." Yang Ruichen pointed, and he was also worried that such a thing would happen. In other words, every project manager was worried that such unexpected things would happen. People are not gods. Any exploration into new fields would pray for good luck, and when bad luck was plagued, everyone would fail.

"Yes, so if the second phase of the clinical trial failed, our project team was disbanded." Fan Lunding paused for a moment and said: "In fact, there are many reasons for the failure. No backup drugs are just one of them. It is also a big problem that we have prepared too little active substances in the early stage."

"How many active substances have you synthesized?" Wei Zhenxue naturally followed his words.

"Six types. Our project team is not very important. Because it has been reorganized once, its competitiveness is not as good as other projects, so it is relatively difficult to synthesize less active substances. As a result, there are fewer active substances passed by animal experiments. When the first phase of clinical trials, there are no choices. There are problems in the second phase of clinical trials and there is no reserve. It can only be declared that the project has failed..." Fan Lunding told the truth, without a lie.

There are few active substances synthesized, which is such a disadvantage. Although the 6 active substances are slightly more synthesized than small companies, they are pitiful enough. Normal small pharmaceutical companies will not think that they will invest so much through the second or even the third phase of the clinical phase, and their capital will not allow them to invest so much.

Wei Zhenxue's face changed slightly and asked: "You have prepared a total of 6 active substances, all of them?"

Fan Lunding thought he was scared by Wei Zhenxue, and quickly explained: "We have been doing it for nearly a year and we exhausted everyone. At that time, our synthesis work was not going well, so we finally prepared 6 types. If your goal is to make a finished product medicine for deferrosterone, I think the standard for the 6 active substances is not high."

"Of course not high." Wei Zhenxue muttered.

"Huh?" Van Lunding didn't understand much.

"We have made 12 kinds, which are exactly twice as much as you said." Wei Zhenxue curled his lips and said, "Yang Rui is still ready to continue doing it."

"I agree with your point of view, and you must have sufficient preparations in the early stage." Yang Rui does not understand pharmaceuticals, but he knows the research direction of deferrosterone. Therefore, it is the most correct choice to make large amounts of active substances with deferrosterone structure and cover them as comprehensively as possible.

Fan Lunding prepared a lot of persuasion, but as soon as he started, he couldn't use it anymore... It was said that his purpose had been achieved, but looking at Yang Rui's confident expression and the positive atmosphere in the laboratory, Fan Lunding felt inexplicably sad.
Chapter completed!